Wire · opportunities
FDA halts release of new drug rejection letters while working to formalize policy
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 9 July 2026 · Fusion42 review
The FDA has temporarily paused its controversial policy of publishing drug rejection letters (CRLs) in real-time, following a pharma industry petition citing risks of exposing proprietary information. The agency is now working to formalize the policy through proposed rulemaking and congressional amendment.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
Biotech founders face regulatory uncertainty around FDA disclosure of rejection rationales—a pause now, but formalization efforts signal this transparency mandate will likely return with codified rules, affecting competitive strategy and data protection practices.
◆ Coverage
1 source · 9 Jul 2026
◆ Related on Wire
◆ Topics